Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 12, 2014, Pages 4462-4470

  Debono, Miguel ^a,c   Bradburn, Mike ^b   Bull, Matthew ^c   Harrison, Barney ^c   Ross, Richard J ^a,c   Newell Price, John ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; BIOLOGICAL MARKER; DEXAMETHASONE;

ADRENAL INCIDENTALOMA; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HUMAN; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; ADRENAL CORTEX TUMOR; ADRENAL TUMOR; BLOOD; MIDDLE AGED; SURVIVAL; VERY ELDERLY;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; DEXAMETHASONE; FEMALE; HUMANS; HYDROCORTISONE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84916620152     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3007     Document Type: Article

References (45)

1. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev. 2004;25:309-340.
2. Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96:1223-1236.
3. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85:637-644.
4. Terzolo M, Pia A, Reimondo G. Subclinical Cushing's syndrome: Definition and management. Clin Endocrinol (Oxf). 2012;76:12-18.
5. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367:1605-1617.
6. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003; 149:273-285.
7. Stewart PM. Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab. 2010;95:2618-2620.
8. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: A large cross-sectional study. Eur J Endocrinol. 2012;166: 669-677.
9. Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: An Italian multicenter study. J Clin Endocrinol Metab. 2014:jc20133527.
10. Di Dalmazi G, Vicennati V, Garelli S, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: A 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2:396-405.
11. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: Cohort study. BMJ. 2012;345:e4928.
12. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001;15:423-432, viii
13. Ntali G, Asimakopoulou A, Siamatras T, et al. Mortality in Cushing's syndrome: Systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013;169:715-723.
14. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: A population-based study. J Clin Endocrinol Metab. 2006;91:4849-4853.
15. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878.
16. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164:851-870.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-349.
18. 2011. Sheffield Director of Public Health Report. http://wwwpublichealthsheffield2011nhsuk/the-story-so-far/cause-of-death/.
19. 2011. Office for National Statistics. http://wwwonsgovuk/ons/rel/vsob1/mortality-statistics-deaths-registered-in-england-and-wales-series-dr-/2010/stb-deaths-by-cause-2010html.
20. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
21. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002;19:1-25.
22. Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C, Salvetti A. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer. 2005;92:1104-1109.
23. Therneau, TM, Grambsch PM. 2000. Modeling survival data: Extending the Cox model. New York: Springer; 350.
24. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503-1510.
25. Chiodini I, Mascia ML, Muscarella S, et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007;147:541-548.
26. Debono M, Prema A, Hughes TJ, Bull M, Ross RJ, Newell-Price J. Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma. J Clin Endocrinol Metab. 2013;98:2383-2391.
27. Dekkers OM, Horváth-Puhó E, Jørgensen JO, et al. Multisystem morbidity and mortality in Cushing's syndrome: A cohort study. J Clin Endocrinol Metab. 2013;98:2277-2284.
28. Lindholm J, Juul S, Jørgensen JO, et al. Incidence and late prognosis of cushing's syndrome:Apopulation-based study. J Clin Endocrinol Metab 2001;86:117-123.
29. Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. Clin Endocrinol (Oxf). 2011;75:436-442.
30. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, Ballotta E. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: A prospective randomized study. Ann Surg. 2009;249:388-391.
31. Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome. Endocr J. 2008;55:737-745.
32. Sereg M, Szappanos A, Toke J, et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: A long-term follow-up study. Eur J Endocrinol. 2009;160:647-655.
33. Jokinen J, Nordström P. HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients. J Affect Disord. 2009;116: 88-92.
34. Dekker MJ, Koper JW, van Aken MO, et al. Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab. 2008;93:3741-3747.
35. Vogelzangs N, Beekman AT, Milaneschi Y, Bandinelli S, Ferrucci L, Penninx BW. Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. J Clin Endocrinol Metab. 2010;95:4959-4964.
36. Alevizaki M, Cimponeriu A, Lekakis J, Papamichael C, Chrousos GP. High anticipatory stress plasma cortisol levels and sensitivity to glucocorticoids predict severity of coronary artery disease in subjects undergoing coronary angiography. Metabolism. 2007;56:222-226.
37. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007;157:545-559.
38. Neary NM, Booker OJ, Abel BS, et al. Hypercortisolism is associated with increased coronary arterial atherosclerosis: Analysis of noninvasive coronary angiography using multidetector computerized tomography. J Clin Endocrinol Metab. 2013;98:2045-2052.
39. del Rincón I, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 2004;50:3813-3822.
40. Mazzoccoli G, De Cata A, Greco A, et al. Aging related changes of circadian rhythmicity of cytotoxic lymphocyte subpopulations. J Circadian Rhythms. 2010;8:6.
41. Blotta MH, DeKruyff RH, Umetsu DT. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol. 1997; 158:5589-5595.
42. Elenkov IJ, Chrousos GP. Stress Hormones, Th1/Th2 patterns, Pro/ Anti-inflammatory Cytokines and Susceptibility to Disease. Trends Endocrinol Metab. 1999;10:359-368.
43. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-1362.
44. Saffar AS, Ashdown H, Gounni AS. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets. 2011;12:556-562.
45. Sharma ST, Yanovski J, Abraham S, Nieman L. Utility of measurement of dexamethasone levels in diagnostic testing for Cushing's syndrome. Program of the 96th Annual Meeting of The Endocrine Society, Chicago, IL, 2014, (Abstract ORO2-1).